These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23894474)

  • 1. Conformational behavior and aggregation of ataxin-3 in SDS.
    Saunders HM; Hughes VA; Cappai R; Bottomley SP
    PLoS One; 2013; 8(7):e69416. PubMed ID: 23894474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
    Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
    Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein.
    Ellisdon AM; Pearce MC; Bottomley SP
    J Mol Biol; 2007 Apr; 368(2):595-605. PubMed ID: 17362987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.
    Kvam E; Nannenga BL; Wang MS; Jia Z; Sierks MR; Messer A
    PLoS One; 2009 May; 4(5):e5727. PubMed ID: 19492089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step.
    Ellisdon AM; Thomas B; Bottomley SP
    J Biol Chem; 2006 Jun; 281(25):16888-16896. PubMed ID: 16624810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.
    Saunders HM; Bottomley SP
    Protein Eng Des Sel; 2009 Aug; 22(8):447-51. PubMed ID: 19589877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigallocatechin-3-gallate and tetracycline differently affect ataxin-3 fibrillogenesis and reduce toxicity in spinocerebellar ataxia type 3 model.
    Bonanomi M; Natalello A; Visentin C; Pastori V; Penco A; Cornelli G; Colombo G; Malabarba MG; Doglia SM; Relini A; Regonesi ME; Tortora P
    Hum Mol Genet; 2014 Dec; 23(24):6542-52. PubMed ID: 25030034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.
    Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P
    Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of ataxin-1-like histidine insertions on polyglutamine aggregation.
    Jayaraman M; Kodali R; Wetzel R
    Protein Eng Des Sel; 2009 Aug; 22(8):469-78. PubMed ID: 19541676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and aggregation of the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in Drosophila melanogaster.
    Ristic G; Sutton JR; Libohova K; Todi SV
    Neurobiol Dis; 2018 Aug; 116():78-92. PubMed ID: 29704548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggregation of polyglutamine-expanded ataxin-3 sequesters its specific interacting partners into inclusions: implication in a loss-of-function pathology.
    Yang H; Li JJ; Liu S; Zhao J; Jiang YJ; Song AX; Hu HY
    Sci Rep; 2014 Sep; 4():6410. PubMed ID: 25231079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNAJB6 is a peptide-binding chaperone which can suppress amyloid fibrillation of polyglutamine peptides at substoichiometric molar ratios.
    Månsson C; Kakkar V; Monsellier E; Sourigues Y; Härmark J; Kampinga HH; Melki R; Emanuelsson C
    Cell Stress Chaperones; 2014 Mar; 19(2):227-39. PubMed ID: 23904097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils.
    Bevivino AE; Loll PJ
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):11955-60. PubMed ID: 11572942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
    Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
    Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3.
    Masino L; Nicastro G; Menon RP; Dal Piaz F; Calder L; Pastore A
    J Mol Biol; 2004 Dec; 344(4):1021-35. PubMed ID: 15544810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse.
    Wang HL; Hu SH; Chou AH; Wang SS; Weng YH; Yeh TH
    Neuropharmacology; 2013 Jul; 70():1-11. PubMed ID: 23347954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small heat-shock proteins interact with a flanking domain to suppress polyglutamine aggregation.
    Robertson AL; Headey SJ; Saunders HM; Ecroyd H; Scanlon MJ; Carver JA; Bottomley SP
    Proc Natl Acad Sci U S A; 2010 Jun; 107(23):10424-9. PubMed ID: 20484674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration.
    Liman J; Deeg S; Voigt A; Voßfeldt H; Dohm CP; Karch A; Weishaupt J; Schulz JB; Bähr M; Kermer P
    J Neurochem; 2014 Jun; 129(6):1013-23. PubMed ID: 24548080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyglutamine tracts regulate beclin 1-dependent autophagy.
    Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
    Nature; 2017 May; 545(7652):108-111. PubMed ID: 28445460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.